The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Self-citationRisk Factors for End-Stage Renal Disease: 25-Year Follow-up
Hsu, C.-Y., Iribarren, C., McCulloch, C. E., Darbinian, J., & Go, A. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.605 · Cited by 589
George, J., Carr, E., Davies, J., Belch, J. J. F., & Struthers, A. (2006) · Circulation · doi:10.1161/circulationaha.106.651117 · Cited by 569
Uric Acid and Incident Kidney Disease in the Community
Weiner, D. E., Tighiouart, H., Elsayed, E. F., Griffith, J. L., Salem, D. N., & Levey, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101075 · Cited by 462
Uric Acid and Long-term Outcomes in CKD
Madero, M., Sarnak, M. J., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Menon, V. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.021 · Cited by 436
Relationship of Uric Acid With Progression of Kidney Disease
Chonchol, M., Shlipak, M. G., Katz, R., Sarnak, M. J., Newman, A. B., Siscovick, D. S., Kestenbaum, B., Carney, J. K., & Fried, L. F. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.05.013 · Cited by 420
Uric acid: A marker of increased cardiovascular risk
Gagliardi, A. C. M., Miname, M. H., & Santos, R. D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.022 · Cited by 384
Noman, A., Ang, D. S., Ogston, S., Lang, C. C., & Struthers, A. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60391-1 · Cited by 348
Kanbay, M., Ozkara, A., Selcoki, Y., Isik, B., Turgut, F., Bavbek, N., Uz, E., Akcay, A., Yigitoglu, R., & Covic, A. (2007) · International Urology and Nephrology · doi:10.1007/s11255-007-9253-3 · Cited by 325
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
“51 56 107 – 110 Therefore, the recommendation to initiate ULTearlier was mainly based on expert opinion but also took into account studies that suggest a cardiovascular 111 112 and renal bene fi t 113 – 116 from xanthine oxidase inhibitors (XOI).”
Romagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.88 · Cited by 996
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179221 · Cited by 595
Uric acid in metabolic syndrome: From an innocent bystander to a central player
Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., Lanaspa, M. A., Nakagawa, T., & Johnson, R. J. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.11.026 · Cited by 419
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.028 · Cited by 383
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 377
Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update
Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018) · Toxins · doi:10.3390/toxins10010033 · Cited by 356
Inflammation in Renal Diseases: New and Old Players
Andrade-Oliveira, V., Foresto-Neto, O., Watanabe, I. K. M., Zatz, R., & Câmara, N. O. S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01192 · Cited by 330
Adenine‐induced chronic kidney disease in rats
Diwan, V., Brown, L., & Gobe, G. C. (2018) · Nephrology · doi:10.1111/nep.13180 · Cited by 273
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
Metadata
- Authors
- Goicoechea, M., Garcia de Vinuesa, S., Verdalles, U., Verde, E., Macias, N., Santos, A., Pérez de Jose, A., Cedeño, S., Linares, T., & Luño, J.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 65
- Issue
- 4
- Pages
- 543-549
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W1997352207
- Cited by
- 302
- References
- 24
- FWCI
- 30.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.